Hospital
Canonsburg General Hospital
Canonsburg General Hospital was paid $2.97M by Medicaid between Jan 2020 and Dec 2024, across 89 billing codes. Its largest line is 99285, emergency room visit (most serious) — 35% of everything it billed.
33Billing provider infoCANONSBURG GENERAL HOSPITAL
CANONSBURG, PA 15317
CANONSBURG, PA 15317
33aNPI1962401497assigned 07/18/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.97M
24GClaims75,325
24DCodes billed89
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#75 of 154
Median peer was paid$2.82M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 4,519 | $117K | |
| 2021 | 27,214 | $802K | |
| 2022 | 15,559 | $685K | |
| 2023 | 16,479 | $754K | |
| 2024incomplete | 11,554 | $615K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 35% | 6,140 | 5,957 | $1.03M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 5,259 | 5,138 | $703K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 5,555 | 5,454 | $599K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 642 | 626 | $87K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 3,851 | 3,705 | $79K |
| 80053 | Comprehensive metabolic panel | 1.7% | 6,492 | 6,159 | $51K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.7% | 706 | 705 | $50K |
| G0378 | Hospital observation service, per hour | 1.5% | 60 | 53 | $45K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.3% | 467 | 460 | $37K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 8,726 | 8,220 | $35K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 2,125 | 2,042 | $32K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,695 | 2,591 | $19K |
77 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 109 | $18K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 332 | $15K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 193 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,891 | $11K |
| 84484 | <1% | 1,621 | $11K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 853 | $10K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 137 | $9K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 138 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 284 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 287 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 990 | $7K |
| 80061 | Lipid panel | <1% | 384 | $6K |
| 83690 | <1% | 1,716 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 531 | $5K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 58 | $5K |
| 80050 | General health panel | <1% | 111 | $5K |
| 0002A | <1% | 117 | $5K | |
| 81001 | <1% | 2,341 | $5K | |
| 81025 | <1% | 1,347 | $4K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 46 | $4K |
| 0001A | <1% | 110 | $4K | |
| 83605 | <1% | 563 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 222 | $3K |
| 83880 | <1% | 117 | $3K | |
| 83735 | <1% | 470 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 247 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 118 | $2K |
| 85379 | <1% | 249 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,432 | $2K |
| 70498 | <1% | 12 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 70 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 239 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 75 | $1K |
| 85610 | <1% | 362 | $1K | |
| 85730 | <1% | 217 | $1K | |
| 86803 | <1% | 69 | $962.98 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 18 | $930.43 |
| 81003 | <1% | 406 | $908.49 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $895.40 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,312 | $838.78 |
| 96376 | <1% | 58 | $791.28 | |
| 84466 | <1% | 27 | $563.71 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 35 | $539.78 |
| 80076 | <1% | 58 | $535.00 | |
| 80305 | <1% | 57 | $535.00 | |
| 87040 | <1% | 30 | $521.92 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $511.32 |
| 84439 | <1% | 56 | $477.64 | |
| 84702 | <1% | 28 | $437.11 | |
| 82728 | <1% | 28 | $421.00 | |
| 82607 | <1% | 32 | $418.36 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 18 | $354.91 |
| 73630 | <1% | 44 | $346.18 | |
| 87081 | <1% | 77 | $318.55 | |
| 73130 | <1% | 40 | $309.60 | |
| 82550 | <1% | 49 | $307.12 | |
| 83540 | <1% | 28 | $280.02 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 55 | $240.80 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,931 | $193.50 |
| 82570 | <1% | 27 | $168.22 | |
| 73560 | <1% | 14 | $145.52 | |
| 84145 | <1% | 12 | $133.27 | |
| 85027 | <1% | 14 | $124.34 | |
| 84703 | <1% | 12 | $111.18 | |
| 85652 | <1% | 40 | $97.50 | |
| 82043 | <1% | 12 | $95.96 | |
| 87186 | <1% | 18 | $93.92 | |
| 84999 | <1% | 27 | $66.56 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,223 | $56.78 |
| 82962 | <1% | 58 | $41.09 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 116 | $33.10 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 289 | $31.36 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 108 | $2.49 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 884 | $0.01 |
| A9270 | Non-covered item or service | 0% | 5,068 | $0.00 |
| J3490 | Unclassified drugs | 0% | 164 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 50 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRIES, RICK (VP, FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Jefferson Regional Medical Center | Clairton, PA | $12.73M |
| West Penn Allegheny Health System INC | Pittsburgh, PA | $12.69M |
| West Penn Allegheny Health System INC. | Pittsburgh, PA | $10.81M |
| West Penn Allegheny Health System INC. | Monroeville, PA | $8.24M |
| Alle-Kiski Medical Center | Natrona Heights, PA | $6.09M |
| Grove City Medical Center | Grove City, PA | $2.17M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.